摘要
探讨血清CYFRA21-1、CA724、AFP联合检测对原发性肝癌(PHC)的诊断价值。选取PHC患者65例、肝硬化患者47例、正常对照组40名,应用电化学发光免疫分析技术检测其血清CYFRA21-1、CA724、AFP水平。结果表明:PHC患者血清AFP、CYFRA21-1、CA724阳性率分别为72.3%、44.6%、35.4%;AFP、CYFRA21-1和CA724三项联合检测阳性率有显著提高,达95.4%,与单一AFP阳性率相比有显著性差异(P<0.05),而特异性无明显下降(P>0.05)。AFP、CY-FRA21-1和CA724联合检测对原发性肝癌的诊断具有良好的临床应用价值。
To explore the clinical value of combined test of serum CYFRA21-1, CA724 and AFP levels in the diagnosis of patients with primary hepatic carcinoma （PHC）. The serum CYFRA21-1, CA724 and AFP levels in 65 patients with primary hepatic carcinoma, 47 patients with cirrhosis, and 40 normal controls were measured by electrochemiluminescence immunoassay. The results showed that the positive rates of serum AFP, CY-FRA21-1 and CA724 in patients with PHC were 72.3% 44.6% and 35.4% separately. The positive rate of combined examination of serum AFP, CYFRA21-1 and CA724 was 95.4% and was significantly higher than that of single AFP test （ P 〈 0.05 ）, but the specificity of combined examination was not higher than that of single AFP test （P 〉0.05）. The combined examination of serum AFP, CYFRA21-1 and CA724 is valuable in the diagnosis of PHC.
出处
《标记免疫分析与临床》
CAS
2009年第1期6-8,共3页
Labeled Immunoassays and Clinical Medicine
